Core Viewpoint - The unexpected tax payment of approximately 16.67 million yuan by Guizhou Baiqiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shenqi Pharmaceutical, adds pressure to the company's growth and will directly impact its 2025 performance [2][5][11]. Financial Impact - The tax payment and late fees amount to 16.67 million yuan, which represents 33.12% of Shenqi Pharmaceutical's net profit of 50.3 million yuan for the first three quarters of 2025 [5][10]. - The company's revenue for the same period was 1.398 billion yuan, indicating that the tax payment significantly affects profitability [5]. Market Reaction - Despite the negative news, the market reacted relatively calmly, with Shenqi Pharmaceutical's stock price closing at 6.48 yuan, a slight increase of 1.25%, and a market capitalization of 3.46 billion yuan [4]. - On November 25, the stock price rose over 4%, influenced by movements in the flu sector [4]. Internal Control Issues - This incident is not the first time Shenqi Pharmaceutical has faced scrutiny over financial compliance, as it previously received regulatory warnings for fabricating consulting fees to misappropriate funds [6][7]. - The tax payment issue highlights potential weaknesses in the company's internal controls and financial oversight of its subsidiaries [11]. Industry Context - Shenqi Pharmaceutical operates in a challenging environment characterized by policy pressures such as volume-based procurement and medical insurance cost control, which affect the pharmaceutical industry as a whole [9]. - The company's high price-to-earnings ratio of 51.6 suggests that its stock price may have already priced in future growth expectations [8].

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

证券日报网讯 11月24日晚间，神奇制药发布公告称，公司下属子公司近期根据主管税务机关要求对涉 税事项开展了自查。经自查，公司下属子公司贵州柏强制药有限公司应补缴企业所得税税款及滞纳金共 计约1，667.12万元。截至本公告披露日，上述税款及滞纳金已缴纳完毕，本次补缴不涉及行政处罚。 （文章来源：证券日报） ...

（原标题：神奇制药(600613.SH)：下属子公司补缴企业所得税税款及滞纳金共计约1667.12万元） 格隆汇11月24日丨神奇制药(600613.SH)公布，经自查，公司下属子公司贵州柏强制药有限公司应补缴 企业所得税税款及滞纳金共计约1,667.12万元。截至本公告披露日，上述税款及滞纳金已缴纳完毕，本 次补缴不涉及行政处罚。 ...

二、对公司的影响及风险提示 | | | 上海神奇制药投资管理股份有限公司 关于全资子公司补缴税款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）下属子公司近期 根据主管税务机关要求对涉税事项开展了自查，现将有关情况公告如下: 一、基本情况 经自查，公司下属子公司贵州柏强制药有限公司应补缴企业所得税税款及 滞纳金共计约 1,667.12 万元。截至本公告披露日，上述税款及滞纳金已缴纳完 毕，本次补缴不涉及行政处罚。 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相 关规定，上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据 追溯调整。上述补缴税款及滞纳金将计入公司 2025 年当期损益，对公司 2025 年度归属于上市公司股东的净利润的影响，最终以 2025 年度经审计的财务报表 为准。敬请广大投资者注意投资风险。 特此公告。 上海神奇制药投资管理股份有限公司董事会 2025 年 11 月 25 日 1 ...

Core Points - The company announced that its subsidiary, Guizhou Baiqiang Pharmaceutical Co., Ltd., needs to pay approximately 16.67 million yuan in corporate income tax and late fees, which has been fully paid as of the announcement date [1] - This matter does not involve administrative penalties and is not classified as a prior accounting error, meaning there will be no retrospective adjustments to previous financial data [1] - The tax payment and late fees will be recorded in the company's profit and loss for the year 2025, with the impact on the net profit for 2025 to be determined based on audited financial statements [1]

格隆汇11月24日丨神奇制药(600613.SH)公布，经自查，公司下属子公司贵州柏强制药有限公司应补缴 企业所得税税款及滞纳金共计约1,667.12万元。截至本公告披露日，上述税款及滞纳金已缴纳完毕，本 次补缴不涉及行政处罚。 ...

人民财讯11月24日电，神奇制药（600613）11月24日公告，经自查，公司下属子公司贵州柏强制药有限 公司应补缴企业所得税税款及滞纳金共计约1667.12万元。截至公告披露日，上述税款及滞纳金已缴纳 完毕，本次补缴不涉及行政处罚。上述补缴税款及滞纳金将计入公司2025年当期损益，对公司2025年度 归属于上市公司股东的净利润的影响，最终以2025年度经审计的财务报表为准。 ...

神奇制药今年以来股价涨2.98%，近5个交易日涨3.91%，近20日涨9.68%，近60日涨0.58%。 资料显示，上海神奇制药投资管理股份有限公司位于上海市威海路128号长发大厦613室，成立日期1992 年7月22日，上市日期1992年8月20日，公司主营业务涉及药品的研发、生产与销售。主营业务收入构成 为：其他特色产品系列45.33%，抗肿瘤药系列27.73%，中药经典止咳系列8.54%，三高慢病产品系列 5.51%，皮肤外用抗菌系列4.81%，苗药强筋健骨系列4.62%，经典滋补产品系列2.61%，神奇娃娃儿药 系列0.84%。 神奇制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：零售药店、医药电商、 抗流感、小盘、中药等。 11月17日，神奇制药（维权）盘中下跌2.12%，截至09:54，报6.91元/股，成交4115.37万元，换手率 1.23%，总市值36.90亿元。 资金流向方面，主力资金净流出781.00万元，特大单买入191.68万元，占比4.66%，卖出444.69万元，占 比10.81%；大单买入455.12万元，占比11.06%，卖出983.11万元，占比23.8 ...

证券日报网讯神奇制药（600613）11月14日在互动平台回答投资者提问时表示，公司最新股东户数情 况，敬请关注公司定期报告所披露的相关内容。 ...